echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > NEJM: Prevention of 1/3 of major cardiovascular events Autumn daffodils to treat chronic coronary heart disease added evidence

    NEJM: Prevention of 1/3 of major cardiovascular events Autumn daffodils to treat chronic coronary heart disease added evidence

    • Last Update: 2020-11-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    LoDoCo2, a randomized controlled trial published at the annual meeting of the European Society of Cardiology (ESC) and published simultaneously in the New England Journal of Medicine, provides new supporting evidence for the secondary prevention of alkaloids in patients with chronic coronary heart disease.
    trials showed that in patients with chronic coronary heart disease, the gingulph old drug akidotes effectively prevented nearly one-third of the major cardiovascular events, including heart attacks, strokes, etc.
    Screenshot Source: The latest results from the New England Journal of Medicine large-scale trial were conducted in more than 5,522 patients aged 35-82 (average 66 years) with chronic coronary heart disease, most of whom were men (84.7%), about half had high blood pressure, 18.2% had diabetes and 84.4% had a history of acute coronary syndrome.
    based on standard therapy, subjects were randomly grouped to receive 0.5 mg of autumn daffodils or placebos once a day.
    follow-up time was 28.6 months.
    6.8 percent of patients in the autumn daffodil group and 9.6 percent of placebo patients in the placebo group experienced coronary artery hemodynamic reconstruction due to cardiovascular death, heart attack, isohemic stroke, or isnemic problems, respectively.
    the main endpoint, autumn daffodils significantly reduced the risk by 31%.
    Compared to placebos, autumn daffodils were also associated with a significant reduction in the incidence of five major secondary endpoint events: cardiovascular death, heart attack or isomorphic stroke (4.2% vs 5.7%), a 28% reduction in the risk of autumn daffodil group, and blood transport reconstruction (5.6% vs 8.1%) due to heart attack or isnemic problems; 33%; cardiovascular death or heart attack (3.6% vs 5.0%), 29% reduction in the risk of alkaloid group in autumn, reconstruction of blood transport due to isnemic problems (4.9% vs. 6.4%), 25% reduction in risk of acacid group in autumn, risk of heart infarction (3.0% vs 4.2%), and risk reduction of 30% in the risk of daffodil group in autumn daffodil group.
    researchers have observed that the benefits of alkaloids in autumn have been evident early in the study and have accumulated over time, more significantly.
    , the preventive effects of alkaloids were consistent across 13 subgroups, including those with or without a history of hypertension, diabetes or acute coronary artery syndrome.
    In terms of safety, the severe adverse reactions in the acacid and placebo groups were similar, including hospitalization for infection (5.0% vs. 5.2%), pneumonia (1.7% vs. 2.0%) or gastrointestinal causes (1.9% vs. 1.8%).
    toxicity events occurred in 3 cases per group.
    researchers point out that there may be potentially adverse interactions between kramycin and aphdobinal, but the use of low-dose alkaloids and full-dose statins appears to be safe. One of the lead authors of
    , Dr Mark Nidorf of GenesisCare, a leading Australian clinic, told the ESC conference: "Autumn daffodils do have a broad and consistent effect in a range of clinical subgroups, demonstrating that alkaloids are effective in improving cardiovascular outcomes in those patients we visit on a daily basis.
    " he added that in this trial, the majority (68.2%) of the subjects who under received coronary arterial hemodynamic reconstruction due to acute coronary artery syndrome occurred in a randomised group of 24 months, which meant that the subjects were not "pre-selected high-risk groups", but rather a "very stable" group of patients, similar to those who went to medical facilities for regular check-ups or follow-up visits.
    called for a change in clinical practice as early as seven years ago, Dr. Nidorf led a team that demonstrated in a small trial of 500 patients that low doses of alkaloids could be beneficial for patients with coronary heart disease.
    , a number of trials around the world have been conducted to explore the use of autumn daffodils for cardiovascular disease.
    Regarding the potential mechanisms for the use of the anti-inflammatory drug alkaloid for cardiovascular disease prevention, Dr. Nidorf said, "We now know that when cholesterol enters the artery wall, it spontaneously forms crystals, just like gash crystals, which can cause a low inflammatory response, leading to long-term scarring of the arteries."
    this inflammation increases, it can cause plaques to rupture, which can lead to heart attacks and strokes.
    " is now again positive, in Dr. Nidorf's view, "a ground-breaking, change-of-practice outcome."
    the long-term use of low doses of daffodils is safe and does not increase the risk of bleeding or hypotension, so it is suitable for use with existing therapies and may become a cornerstone therapy for patients with coronary heart disease together with aspirin and statins."
    , autumn daffodils are cheap and widely available.
    Dr. Paul Ridker, Director of the Cardiovascular Disease Prevention and Control Center at Brigham and Women's Hospital, commented, "The results of three important double-blind placebo-controlled trials, including CANTOS, COLCOT, and LoDoCo2, are highly consistent, which is enough to change clinical practice."
    " References: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Colchicine in Patients with Chronic Coronary Disease. N Engl J Med, DOI: 10.1056/NEJMoa2021372 Retrieved September 3, 2020, from. Retrieved September 3, 2020, from Common medicine used to treat gout found to prevent progression of coronary disease. Retrieved September 3, 2020, from Original title: NEJM: Prevention of 1/3 major cardiovascular events, gyrophic old drug Akida to treat chronic coronary heart disease added evidence
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.